Substituted pyridobenzodiazepinone-derivatives and use thereof

US10047096B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Andreas Schall · Wuppertal, DE
• Jürgen Klar · Wuppertal, DE
• Mario Lobell · Wuppertal, DE
• Hartmut Schirok · Wuppertal, DE
• Joachim Telser · Wuppertal, DE
• Steffen Müller · Essen, DE
• Dirk Brohm · Mettmann, DE
• Hans Briem · Bremen, DE
• Hannah Jörißen · Heiligenhaus, DE
• Joerg Keldenich · Wuppertal, DE
• Michael Bottger · Wuppertal, DE
• Georges Von Degenfeld · Leverkusen, DE
• Thomas Schlange · Haan, DE
• Ulf Bömer · Glienicke, DE
• Niels Lindner · Wuppertal, DE
• Hanna Eilken · Wuppertal, DE
• Dmitrij Hristodorov · Wuppertal, DE
• Pierre Wasnaire · Mülheim an der Ruhr, DE
• Kersten Matthias Gericke · Wuppertal, DE
• Lars Bärfacker · Oberhausen, DE

Key dates

• Filing date: Nov 23, 2015
• Grant date: Aug 14, 2018
• Expiry date: Nov 23, 2035

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.